John Mascarenhas, MD

Articles

Looking Deeper Inside Myelofibrosis

September 28th 2021

Dr. Mascarenhas on Potential for Pacritinib to Address an Unmet Need in Myelofibrosis

June 17th 2021

John O. Mascarenhas, MD, discusses the potential for pacritinib to address an unmet need in the treatment of patients with myelofibrosis.

Dr. Mascarenhas on the Promise of Imetelstat in Myelofibrosis

November 4th 2020

John O. Mascarenhas, MD, discusses the promise of imetelstat in myelofibrosis.

Dr. Mascarenhas on Limitations With JAK Inhibitors in Myelofibrosis

November 4th 2020

John O. Mascarenhas, MD, discusses limitations with JAK inhibitors in myelofibrosis.

Dr. Mascarenhas Discusses Ongoing Clinical Trials in Myelofibrosis

August 12th 2020

John O. Mascarenhas, MD, discusses ongoing clinical trials in myelofibrosis.

Dr. Mascarenhas on Approved and Emerging Treatment Options in Myelofibrosis

August 6th 2020

John O. Mascarenhas, MD, discusses approved and emerging treatment options in myelofibrosis.

Dr. Mascarenhas Discusses Pacritinib in Myelofibrosis

February 20th 2017

John Mascarenhas, MD, associate professor of Medicine, Mount Sinai School of Medicine, discusses pacritinib in patients with myelofibrosis.

Dr. Mascarenhas on the MPD-RC 112 Study in PV and ET

December 30th 2016

John Mascarenhas, MD, associate professor of Medicine, Mount Sinai School of Medicine, discusses the results from the interim analysis of the MPD-RC 112 study, which compared frontline pegylated interferon-alpha-2a with hydroxyurea in the treatment of patients with high risk polycythemia vera and essential thrombocythemia.